Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share. Aerie Pharmaceuticals develops treatments for patients with glaucoma and other eye diseases. Aerie's two main products are intraocular pressure-lowering drugs and treatments for patients with glaucoma or ocular hypertension.

Alcon buys Aerie Pharmaceuticals for $770 million, or 15.25 per share. Aerie Pharmaceuticals develops treatments for patients with glaucoma and other eye diseases. Aerie's two main products are drugs to reduce intraocular pressure and to treat patients with glaucoma or ocular hypertension. Deal is scheduled to close in the fourth quarter of 2022.

Alcon's GAAP net income for the 3 months of 2022 was $168 million, up twofold from $84 million in the previous year. Revenue increased 13.4% to $2.189 billion from $1.93 billion a year earlier.

Alcon's IFRS net income for 2021 was $376 million, compared to a loss of $531 million in the previous year. Revenue increased by 21.3% to $8.291 billion from $6.833 billion a year earlier.